Appendicitis After Initiation of Tirzepatide
Garrett Chan1, Mariam Ansar1, Marlena Klein1,21Department of Internal Medicine, Cooper University Hospital, Camden, New Jersey, USA; 2Cooper Medical School of Rowan University, Camden, New Jersey, USACorrespondence: Garrett Chan, Email chan-garrett@cooperhealth.eduAbstract: Tirzepatide is a GLP1/GIP...
Saved in:
Main Authors: | Chan G, Ansar M, Klein M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-01-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Subjects: | |
Online Access: | https://www.dovepress.com/appendicitis-after-initiation-of-tirzepatide-peer-reviewed-fulltext-article-DMSO |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01) -
Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes
by: Wiktor Biesiada, et al.
Published: (2025-01-01) -
Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01) -
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis
by: Song Liu, et al.
Published: (2025-02-01) -
Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)